会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 96. 发明申请
    • PEPTIDE COMPOSITIONS WITH GROWTH FACTOR-LIKE ACTIVITY
    • 具有生长因子活性的肽组合物
    • WO1998018816A1
    • 1998-05-07
    • PCT/US1997018342
    • 1997-10-10
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIABHATNAGAR, Rajendra, S.QIAN, Jing, Jing
    • C07K07/06
    • C07K7/06A61K38/00A61L27/227C07K14/495
    • Small peptide mimics of TGF- beta , having the general sequence AAj-AAj+1-AAj+2 followed by AAi+n shortly thereafter, have been prepared. In this sequence, AAi is alanine, asparagine, or leucine, AAi+1 is valine or isoleucine, AAi+2 is alanine, n is 3, 4 or 5 such that there are n-3 amino acid residues in between AAj+2 and AAi+n, and AAj+n is glutamic acid, aspartic acid, glutamine or asparagine. Because the essential requirement for TGF- beta activity is the peptide's ability to form a stable beta -bend structure under physiologic conditions, the inventive peptides are collectively referred to as beta -bend peptides. Compositions for applications such as tissue repair are also provided that comprise a biocompatible matrix having cytomodulin or a cytomodulin analog admixed with or carried by the matrix.
    • 已经制备了具有一般序列AAj-AAj + 1-AAj + 2,之后是AAi + n的TGF-β的小肽模拟物。 在这个序列中,AAi是丙氨酸,天冬酰胺或亮氨酸,AAi + 1是缬氨酸或异亮氨酸,AAi + 2是丙氨酸,n是3,4或5,使得在AAj + 2之间有n-3个氨基酸残基 AAi + n和AAj + n是谷氨酸,天冬氨酸,谷氨酰胺或天冬酰胺。 因为TGF-β活性的基本要求是肽在生理条件下形成稳定的β-末端结构的能力,所以本发明的肽统称为β-末端肽。 还提供了诸如组织修复的组合物,其包含具有与基质混合或携带的细胞调节蛋白或细胞模型蛋白类似物的生物相容性基质。
    • 98. 发明申请
    • A COMPOSITION COMPRISING AN IMMOBILISED, ACYLATED PEPTIDE
    • 包含固定化的肽的组合物
    • WO1998015572A1
    • 1998-04-16
    • PCT/EP1997005572
    • 1997-10-07
    • AKZO NOBEL N.V.LOOMANS, Elma, Elisabeth, Maria, GerardaSCHIELEN, Wilhelmus, Joseph, Gerardus
    • AKZO NOBEL N.V.
    • C07K07/06
    • C07K17/06G01N33/54353
    • A novel generic coating procedure to improve the coating efficienncy of small synthetic peptide antigens in ELISA is described. Inthis invention the binding capacities of several peptides linked to various moieties were compared to their parent counterparts in ELISA. Elongation of an epitope-sequence by an acyl group of the formula: R1-A-R2-CO- wherein R1 is lower alkyl, arly, or aralkyl; R2 is a divalent radical derived from lower alkyl, arly, or aralkyl; and A is a sulfur containing functional group selected from -CO-S-, -S-, -SO-, -SO2- and -S-S- specifically increased the binding reactivity with the monoclonal antibody when adsorbed onto a solid support, preferably polystyrene wells. Elongation is preferably, N-teminally. Several moieties achieved an enormous reduction in peptide coat concentration for all tested peptides of net two to four orders of magnitude. Replacement of an Ata-extension (wherein R1 is methyl; R2 is methylene; and A is -CO-S-) by analogues (i.e. Bta, Atp, Btb) was possible without reducing their enhancing properties to a great extent. Furthermore, direct synthesis of the Ata-group to the N-terminal end of a peptide appears to be a simple and general strategy for effective adsorption of small peptides to polystyrene.
    • 描述了一种用于改善ELISA中小合成肽抗原的包衣效率的新颖的通用包衣方法。 本发明将与多种部分连接的几种肽的结合能力与ELISA中的亲本对应物进行比较。 通过下式的酰基延伸表位序列:R1-A-R2-CO-,其中R1是低级烷基,芳基或芳烷基; R2是衍生自低级烷基,芳基或芳烷基的二价基团; 并且A是选自-CO-S-,-S-,-SO-,-SO 2 - 和-SS的含硫官能团 - 当吸附到固体载体上时,特别是增加了与单克隆抗体的结合反应性,优选聚苯乙烯 。 延伸优选为N末端。 对于所有测试的肽的肽数量来说,几个部分实现了肽包衣浓度的极大降低。 通过类似物(即Bta,Atp,Btb)替换Ata-延伸(其中R1是甲基; R2是亚甲基; A是-CO-S-))是可能的,而在很大程度上不降低它们的增强性能。 此外,将Ata-基团直接合成肽的N-末端似乎是有效吸附小肽至聚苯乙烯的简单且一般的策略。
    • 99. 发明申请
    • TRI- OR POLYSULPHIDE CONTAINING PEPTIDES HAVING IMMUNOMODULATING ACTIVITY
    • 具有免疫调节活性的含有多聚磷酸的肽
    • WO1998012218A1
    • 1998-03-26
    • PCT/SE1997001553
    • 1997-09-15
    • ASTRA AKTIEBOLAG (publ)BERGSTRAND, HåkanERIKSSON, TomasLINDVALL, MagnusSÄRNSTRAND, Bengt
    • ASTRA AKTIEBOLAG (publ)
    • C07K07/06
    • C07K7/06A61K38/00
    • A physiologically active tri- or polysulphide linked peptide homo- or heterodimer or cyclised monomer, derived from one or more monomers of formula (I): A-R2-R3-B (SEQ ID NO:1) wherein R2 is a residue of an amino acid selected from proline (Pro), isoleucine (Ile), alanine (Ala), tyrosine (Tyr), pipecolic acid (Pec), threonine (Thr), arginine (Arg), glycine (Gly), or R8, R3 is R8, and each R8 is independently an amino acid residue of formula (II) or formula (III), wherein each of R5 and R6 is independently selected from H, alkyl, e.g. methyl, aryl and alkoxy, n is selected from 0, 1, 2, 3 and 4, and m is selected from 0, 1, 2, 3 and 4; the entire peptide sequence of each monomer containing 3 to 30 amino acid residues; the dimer being formed by linking of the sulphide group of at least one R8 group of one monomer to the sulphide group of an R8 group of the other monomer via an -(S)p- wherein p is an integer of at least 1, so that a trisulphide or polysulphide link is provided, and the monomer being cyclised by linking of the sulphide group of one R8 group to the sulphide group of another R8 group via an -(S)p-, wherein p is an integer of at least 1, so that a trisulphide or polysulphide cyclising link is provided, is absorbable by the epithelial cell lining in a mammal resulting in a modulated immune response and thereby a therapeutic effect against disease.
    • 衍生自一种或多种式(I)单体的生理活性三硫或多硫键连接的肽均聚物或异二聚体或环化单体:A-R2-R3-B(SEQ ID NO:1),其中R2是 选自脯氨酸(Pro),异亮氨酸(Ile),丙氨酸(Ala),酪氨酸(Tyr),哌啶酸(Pec),苏氨酸(Thr),精氨酸(Arg),甘氨酸(Gly)或R8, R 8和R 8各自独立地为式(II)或式(III)的氨基酸残基,其中R 5和R 6各自独立地选自H,烷基,例如 甲基,芳基和烷氧基,n选自0,1,2,3和4,m选自0,1,2,3和4; 每个单体的整个肽序列含有3至30个氨基酸残基; 二聚体通过一个单体的至少一个R 8基团的硫化物基团与其它单体的R 8基团的硫化物基团经由其中p是至少为1的整数连接而形成,因此, 提供三硫化物或多硫化物连接,并且单体通过将一个R 8基团的硫化物基团与另一个R 8基团的硫化物基团经由 - (S)p - 键合而环化,其中p是至少为1的整数 ,使得提供三硫化物或多硫化物环化链接,其可被哺乳动物中的上皮细胞衬里吸收,导致调节的免疫应答,从而对抗疾病的治疗效果。